



Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A method for inhibiting platelet deposition associated with the use of a medical device in a patient in need thereof comprising locally administering a therapeutically effective amount of a nitric oxide adduct to the patient to inhibit platelet deposition; wherein the nitric oxide adduct is an angiotensin converting enzyme inhibitor which has at least one -O-NO₂ group.
- 2-4. (Cancelled)
5. (Currently Amended) The method of claim 1, further comprising administering at least one anti-thrombogenic compound or a therapeutic agent.
6. (Currently Amended) The method of claim 5, wherein the anti-thrombogenic compound is heparin, hirudin, an analog of hirudin, warfarin, aspirin, indomethacin, dipyridamole, prostacyclin, prostaglandin-E, a sulfinpyrazone, a phenothiazine, a RGD peptide, a RDG peptide mimetic, an agent that blocks platelet glycoprotein IIb IIIa receptors, ticlopidine or clopidogrel.
7. (Cancelled)
8. (Currently Amended) A method for alleviating restenosis associated with the use of a medical device in a patient in need thereof comprising locally administering a therapeutically effective amount of a nitric oxide adduct to the patient to alleviate restenosis; wherein the nitric oxide adduct is an angiotensin converting enzyme inhibitor which has at least one -O-NO₂ group.
- 9-11. (Cancelled)
12. (Currently Amended) The method of claim 8, further comprising administering at least one anti-thrombogenic compound or a therapeutic agent.
13. (Currently Amended) The method of claim 12, wherein the anti-thrombogenic compound is heparin, hirudin, an analog of hirudin, warfarin, aspirin, indomethacin, dipyridamole, prostacyclin, prostaglandin-E, a sulfinpyrazone, a phenothiazine, a RGD peptide, a RDG peptide mimetic, an agent that blocks platelet glycoprotein IIb IIIa receptors, ticlopidine or clopidogrel.
14. (Cancelled)

15. (Currently Amended) A method for treating a vascular complication caused by platelet deposition or thrombus formation associated with the use of a medical device in a patient in need thereof comprising locally administering a therapeutically effective amount of a nitric oxide adduct to the patient to treat the vascular complication caused by platelet deposition or thrombus formation associated with the use of a medical device; wherein the vascular complication caused by platelet deposition or thrombus formation is myocardial infarction, thrombophlebitis, thrombocytopenia or bleeding disorder; wherein the nitric oxide adduct is an angiotensin converting enzyme inhibitor which has at least one -O-NO₂ group.

16.-18. (Cancelled)

19. (Currently Amended) The method of claim 15, further comprising administering at least one anti-thrombogenic compound ~~or a therapeutic agent~~.

20. (Currently Amended) The method of claim 19, wherein the anti-thrombogenic compound is heparin, hirudin, an analog of hirudin, warfarin, aspirin, indomethacin, dipyridamole, prostacyclin, prostaglandin-E, a sulfinpyrazone, a phenothiazine, a RGD peptide, a RGD peptide mimetic, an agent that blocks platelet glycoprotein IIb-IIIa receptors, ticlopidine or clopidogrel.

21. (Cancelled)

22. (Currently Amended) A method for inhibiting platelet deposition, platelet adhesion or thrombus formation associated with the use of a medical device in a patient in need thereof comprising locally administering a therapeutically effective amount of a nitric oxide adduct to the patient to treat a myocardial infarction, thrombophlebitis, thrombocytopenia or a bleeding disorder caused by the platelet deposition, platelet adhesion or the thrombus formation; wherein the nitric oxide adduct is an angiotensin converting enzyme inhibitor which has at least one -O-NO₂ group.

23-25 (Cancelled)

26. (Currently Amended) The method of claim 22, further comprising administering at least one anti-thrombogenic compound ~~or a therapeutic agent~~.

27. (Currently Amended) The method of claim 26, wherein the anti-thrombogenic compound is heparin, hirudin, an analog of hirudin, warfarin, aspirin, indomethacin, dipyridamole, prostacyclin, prostaglandin-E, a sulfinpyrazone, a phenothiazine, a RGD peptide, a

~~RGD peptide mimetic, an agent that blocks platelet glycoprotein IIb-IIIa receptors, ticlopidine or clopidogrel.~~

28. (Cancelled)

29. (Currently Amended) A method for treating a dysfunction in the endothelium of a patient associated with the use of a medical device comprising locally administering a therapeutically effective amount of a nitric oxide adduct to the patient wherein the nitric oxide adduct is an angiotensin converting enzyme inhibitor which has at least one -O-NO₂ group.

30-32 (Cancelled)

33. (Currently Amended) The method of claim 29, further comprising administering at least one anti-thrombogenic compound ~~or a therapeutic agent~~.

34. (Currently Amended) The method of claim 33, wherein the anti-thrombogenic compound is heparin, hirudin, an analog of hirudin, warfarin, aspirin, indomethacin, dipyridamole, prostacyclin, prostaglandin-E, a sulfinpyrazone, a phenothiazine, a RGD peptide, a ~~RGD peptide mimetic, an agent that blocks platelet glycoprotein IIb-IIIa receptors, ticlopidine or clopidogrel.~~

35. (Cancelled)